251 related articles for article (PubMed ID: 19144941)
1. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C.
Rodriguez-Torres M; Jeffers LJ; Sheikh MY; Rossaro L; Ankoma-Sey V; Hamzeh FM; Martin P;
N Engl J Med; 2009 Jan; 360(3):257-67. PubMed ID: 19144941
[TBL] [Abstract][Full Text] [Related]
2. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
Hézode C; Forestier N; Dusheiko G; Ferenci P; Pol S; Goeser T; Bronowicki JP; Bourlière M; Gharakhanian S; Bengtsson L; McNair L; George S; Kieffer T; Kwong A; Kauffman RS; Alam J; Pawlotsky JM; Zeuzem S;
N Engl J Med; 2009 Apr; 360(18):1839-50. PubMed ID: 19403903
[TBL] [Abstract][Full Text] [Related]
3. Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection.
Rodriguez-Torres M; Lawitz E; Yangco B; Jeffers L; Han SH; Thuluvath PJ; Rustgi V; Harrison S; Ghalib R; Vierling JM; Luketic V; Zamor PJ; Ravendhran N; Morgan TR; Pearlman B; O'Brien C; Khallafi H; Pyrsopoulos N; Kong G; McPhee F; Yin PD; Hughes E; Treitel M
Ann Hepatol; 2016 Nov-Dec 2016; 15(6):834-845. PubMed ID: 27740516
[TBL] [Abstract][Full Text] [Related]
4. Peginterferon α-2a plus ribavirin in Latino and Non-Latino Whites with HCV genotype 1: Histologic outcomes and tolerability from the LATINO Study.
Balart LA; Lisker-Melman M; Hamzeh FM; Kwok A; Lentz E; Rodriguez-Torres M;
Am J Gastroenterol; 2010 Oct; 105(10):2177-85. PubMed ID: 20389293
[TBL] [Abstract][Full Text] [Related]
5. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
6. Telaprevir for retreatment of HCV infection.
Zeuzem S; Andreone P; Pol S; Lawitz E; Diago M; Roberts S; Focaccia R; Younossi Z; Foster GR; Horban A; Ferenci P; Nevens F; Müllhaupt B; Pockros P; Terg R; Shouval D; van Hoek B; Weiland O; Van Heeswijk R; De Meyer S; Luo D; Boogaerts G; Polo R; Picchio G; Beumont M;
N Engl J Med; 2011 Jun; 364(25):2417-28. PubMed ID: 21696308
[TBL] [Abstract][Full Text] [Related]
7. Sofosbuvir for previously untreated chronic hepatitis C infection.
Lawitz E; Mangia A; Wyles D; Rodriguez-Torres M; Hassanein T; Gordon SC; Schultz M; Davis MN; Kayali Z; Reddy KR; Jacobson IM; Kowdley KV; Nyberg L; Subramanian GM; Hyland RH; Arterburn S; Jiang D; McNally J; Brainard D; Symonds WT; McHutchison JG; Sheikh AM; Younossi Z; Gane EJ
N Engl J Med; 2013 May; 368(20):1878-87. PubMed ID: 23607594
[TBL] [Abstract][Full Text] [Related]
8. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C;
N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352
[TBL] [Abstract][Full Text] [Related]
9. Telaprevir for previously treated chronic HCV infection.
McHutchison JG; Manns MP; Muir AJ; Terrault NA; Jacobson IM; Afdhal NH; Heathcote EJ; Zeuzem S; Reesink HW; Garg J; Bsharat M; George S; Kauffman RS; Adda N; Di Bisceglie AM;
N Engl J Med; 2010 Apr; 362(14):1292-303. PubMed ID: 20375406
[TBL] [Abstract][Full Text] [Related]
10. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites.
Muir AJ; Bornstein JD; Killenberg PG;
N Engl J Med; 2004 May; 350(22):2265-71. PubMed ID: 15163776
[TBL] [Abstract][Full Text] [Related]
11. Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.
Berak H; Laskus T; Kołakowska-Rządzka A; Wasilewski M; Stańczak JJ; Bardadin K; Walewska-Zielecka B; Horban A
Adv Med Sci; 2014 Sep; 59(2):261-5. PubMed ID: 25117425
[TBL] [Abstract][Full Text] [Related]
12. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
[TBL] [Abstract][Full Text] [Related]
13. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin.
Rustgi VK; Esposito S; Hamzeh FM; Shiffman ML
Aliment Pharmacol Ther; 2008 Mar; 27(5):433-40. PubMed ID: 18081737
[TBL] [Abstract][Full Text] [Related]
14. Equally poor outcomes to pegylated interferon-based therapy in African Americans and Hispanics with chronic hepatitis C infection.
Satapathy SK; Lingisetty CS; Proper S; Chaudhari S; Williams S
J Clin Gastroenterol; 2010 Feb; 44(2):140-5. PubMed ID: 19826275
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population.
Rodriguez-Torres M; Sulkowski MS; Chung RT; Hamzeh FM; Jensen DM
J Viral Hepat; 2010 Feb; 17(2):139-47. PubMed ID: 19674282
[TBL] [Abstract][Full Text] [Related]
16. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
McHutchison JG; Everson GT; Gordon SC; Jacobson IM; Sulkowski M; Kauffman R; McNair L; Alam J; Muir AJ;
N Engl J Med; 2009 Apr; 360(18):1827-38. PubMed ID: 19403902
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders.
Gane EJ; Rouzier R; Wiercinska-Drapalo A; Larrey DG; Morcos PN; Brennan BJ; Le Pogam S; Nájera I; Petric R; Tran JQ; Kulkarni R; Zhang Y; Smith P; Yetzer ES; Shulman NS
Antimicrob Agents Chemother; 2014; 58(2):1136-45. PubMed ID: 24295986
[TBL] [Abstract][Full Text] [Related]
18. Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response.
Howell CD; Jeffers LS; Cassidy W; Reddy KR; Hu S; Lee JS
J Viral Hepat; 2006 Jun; 13(6):371-6. PubMed ID: 16842439
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients.
Méndez-Navarro J; Chirino RA; Corey KE; Gorospe EC; Zheng H; Morán S; Juarez JA; Chung RT; Dehesa-Violante M
Dig Dis Sci; 2010 Sep; 55(9):2629-35. PubMed ID: 19960257
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C viral kinetics in Latino patients: a comparison to African American and Caucasian patients.
Rodríguez-Torres M; Burguera J; Hallman D; Rodríguez-Orengo J; Echeandia M
Ann Hepatol; 2012; 11(4):450-63. PubMed ID: 22700626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
